AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635, Demonstrating Significant Reduction in Frequency and Severity of Vasomotor Symptoms and a Favorable Tolerability Profile
Business Wire•10/08/2026•07:00 ET
0
Whiz Insights
Get started
Create a free account to read the full story.